Table 2.
Number of events, person years, crude and standardised incidence rates and HRs, for all cancers other than NMSC, and for cancer sites where at least five incident events were observed in the JAK cohort, in Swedish patients with RA treated with JAKi, non-TNFi bDMARDs or TNFi
| Cohort | Events | Person years, no | Crude incidence rate per 1000 person-years | Standardised incidence rate per 1000 person-years | Fully adjusted HR* |
| All cancers other than NMSC | |||||
| All JAKi | 38 | 3996 | 9.5 | 8.3 | 0.94 (0.65 to 1.38) |
| Tofacitinib | 8 | 793 | 10.1 | 11.2 | 1.08 (0.52 to 2.24) |
| Baricitinib | 30 | 3187 | 9.4 | 8.0 | 0.92 (0.61 to 1.38) |
| Non-TNFi bDMARD† | 141 | 11 051 | 12.8 | 10.5 | 1.12 (0.88 to 1.43) |
| TNFi | 213 | 21 122 | 10.1 | 10.1 | 1.0 (Reference) |
| General population | 1245 | 128 224 | 9.7 | 9.2 | n/a |
| NMSC | |||||
| All JAKi | 59 | 3954 | 14.9 | 12.9 | 1.39 (1.01 to 1.91) |
| Tofacitinib | 11 | 781 | 14.1 | 14.9 | 1.56 (0.83 to 2.92) |
| Baricitinib | 48 | 3157 | 15.2 | 12.5 | 1.37 (0.97 to 1.92) |
| Non-TNFi bDMARD† | 126 | 11 027 | 11.4 | 9.0 | 1.00 (0.78 to 1.28) |
| TNFi | 189 | 21 083 | 9.0 | 9.0 | 1.0 (Reference) |
| General population | 852 | 128 630 | 6.6 | 6.2 | n/a |
| Breast cancer | |||||
| All JAKi | 7 | 4014 | 1.7 | 1.6 | 0.73 (0.29 to 1.86) |
| Tofacitinib | 1 | 797 | 1.3 | – | – |
| Baricitinib | 6 | 3201 | 1.9 | 1.7 | 0.77 (0.29 to 2.06) |
| Non-TNFi bDMARD† | 23 | 11 197 | 2.1 | 1.9 | 0.88 (0.48 to 1.61) |
| TNFi | 42 | 21 328 | 2.0 | 2.0 | 1.0 (Reference) |
| General population | 262 | 129 601 | 2.0 | 2.0 | n/a |
| All haematopoietic | |||||
| All JAKi | 6 | 4018 | 1.5 | 1.5 | 1.90 (0.70 to 5.16) |
| Tofacitinib | 1 | 798 | 1.3 | – | – |
| Baricitinib | 5 | 3203 | 1.6 | 1.6 | 1.96 (0.66 to 5.79) |
| Non-TNFi bDMARD† | 12 | 11 217 | 1.1 | 0.9 | 1.04 (0.48 to 2.25) |
| TNFi | 22 | 21 359 | 1.0 | 1.0 | 1.0 (Reference) |
| General population | 99 | 129 854 | 0.8 | 0.7 | n/a |
| Lung cancer | |||||
| All JAKi | 7 | 4021 | 1.7 | 1.5 | 1.15 (0.57 to 2.32) |
| Tofacitinib | 2 | 798 | 2.5 | – | – |
| Baricitinib | 5 | 3206 | 1.6 | 1.2 | 0.98 (0.44 to 2.23) |
| Non-TNFi bDMARD† | 11 | 11 224 | 1.0 | 0.7 | 0.59 (0.31 to 1.15) |
| TNFi | 30 | 21 368 | 1.4 | 1.4 | 1.0 (Reference) |
| General population | 111 | 129 912 | 0.9 | 0.8 | n/a |
Estimated from Cox proportional hazards models. Standardised incidence rate standardised to the age and sex distribution in the TNFi cohort. – is displayed when too few events (<5) were observed.
*Fully adjusted HR: adjusted for age, sex, line of therapy, for comorbidities, SES, disease-related factors and with missing categories included for those variables with missing information.
†Non-TNFI bDMARD includes rituximab, abatacept, tocilizumab.
bDMARD, biological disease-modifying antirheumatic drug; JAKi, Janus kinas inhibitor; n/a, not available; NMSC, non-melanoma skin cancer; RA, rheumatoid arthritis; SES, socioeconomic status; TNFi, tumour necrosis factor inhibitor.